China’s answer to the Asco conference, remarkably now in its 22nd year, reminds western investors of the country’s oncology prowess.
Astra’s Caspian study is the star of next week’s World Lung conference, which has also given targeted approaches important supporting roles.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
A look at sector share prices in the opening three months of 2019 reveals a resurgent big pharma and a strong showing from the world’s other large drug makers, with US…
A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?
But Erleada, Johnson & Johnson’s next-gen prostate cancer therapy, still needs to outperform the incumbent, Zytiga.
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.